Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma - Trial NCT06417892
Access comprehensive clinical trial information for NCT06417892 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
N/A
May 15, 2024
Nov 30, 2026
Primary Outcome
PFS
Summary
To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or
 without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal
 junction adenocarcinoma that failed to be treated by anti-PD-1 /PD-L1 regimen
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06417892
Non-Device Trial